156 related articles for article (PubMed ID: 26646757)
1. A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors.
Tolcher AW; Papadopoulos KP; Patnaik A; Wilson K; Thayer S; Zanghi J; Gemo AT; Kavanaugh WM; Keer HN; LoRusso PM
Ann Oncol; 2016 Mar; 27(3):526-32. PubMed ID: 26646757
[TBL] [Abstract][Full Text] [Related]
2. A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.
van Brummelen EMJ; Levchenko E; Dómine M; Fennell DA; Kindler HL; Viteri S; Gadgeel S; López PG; Kostorov V; Morgensztern D; Orlov S; Zauderer MG; Vansteenkiste JF; Baker-Neblett K; Vasquez J; Wang X; Bellovin DI; Schellens JHM; Yan L; Mitrica I; DeYoung MP; Trigo J
Invest New Drugs; 2020 Apr; 38(2):457-467. PubMed ID: 31065954
[TBL] [Abstract][Full Text] [Related]
3. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.
Harding TC; Long L; Palencia S; Zhang H; Sadra A; Hestir K; Patil N; Levin A; Hsu AW; Charych D; Brennan T; Zanghi J; Halenbeck R; Marshall SA; Qin M; Doberstein SK; Hollenbaugh D; Kavanaugh WM; Williams LT; Baker KP
Sci Transl Med; 2013 Mar; 5(178):178ra39. PubMed ID: 23536011
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230.
Blackwell C; Sherk C; Fricko M; Ganji G; Barnette M; Hoang B; Tunstead J; Skedzielewski T; Alsaid H; Jucker BM; Minthorn E; Kumar R; DeYoung MP
Oncotarget; 2016 Jun; 7(26):39861-39871. PubMed ID: 27223434
[TBL] [Abstract][Full Text] [Related]
5. An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer.
Morgensztern D; Karaseva N; Felip E; Delgado I; Burdaeva O; Dómine M; Lara P; Paik PK; Lassen U; Orlov S; Trigo J; Shomova M; Baker-Neblett K; Vasquez J; Wang X; Yan L; Mitrica I; DeYoung MP; Garrido P
Lung Cancer; 2019 Oct; 136():74-79. PubMed ID: 31446228
[TBL] [Abstract][Full Text] [Related]
6. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors.
Bahleda R; Meric-Bernstam F; Goyal L; Tran B; He Y; Yamamiya I; Benhadji KA; Matos I; Arkenau HT
Ann Oncol; 2020 Oct; 31(10):1405-1412. PubMed ID: 32622884
[TBL] [Abstract][Full Text] [Related]
7. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
[TBL] [Abstract][Full Text] [Related]
8. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.
Soria JC; DeBraud F; Bahleda R; Adamo B; Andre F; Dientsmann R; Delmonte A; Cereda R; Isaacson J; Litten J; Allen A; Dubois F; Saba C; Robert R; D'Incalci M; Zucchetti M; Camboni MG; Tabernero J
Ann Oncol; 2014 Nov; 25(11):2244-2251. PubMed ID: 25193991
[TBL] [Abstract][Full Text] [Related]
9. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
Ronca R; Giacomini A; Rusnati M; Presta M
Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
[TBL] [Abstract][Full Text] [Related]
10. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
[TBL] [Abstract][Full Text] [Related]
11. Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring
Meric-Bernstam F; Bahleda R; Hierro C; Sanson M; Bridgewater J; Arkenau HT; Tran B; Kelley RK; Park JO; Javle M; He Y; Benhadji KA; Goyal L
Cancer Discov; 2022 Feb; 12(2):402-415. PubMed ID: 34551969
[TBL] [Abstract][Full Text] [Related]
12. Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.
Tabernero J; Bahleda R; Dienstmann R; Infante JR; Mita A; Italiano A; Calvo E; Moreno V; Adamo B; Gazzah A; Zhong B; Platero SJ; Smit JW; Stuyckens K; Chatterjee-Kishore M; Rodon J; Peddareddigari V; Luo FR; Soria JC
J Clin Oncol; 2015 Oct; 33(30):3401-8. PubMed ID: 26324363
[TBL] [Abstract][Full Text] [Related]
13. First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors.
Koyama T; Shimizu T; Iwasa S; Fujiwara Y; Kondo S; Kitano S; Yonemori K; Shimomura A; Iizumi S; Sasaki T; Furuse J; Yamamoto N
Cancer Sci; 2020 Feb; 111(2):571-579. PubMed ID: 31797489
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach.
Presta M; Chiodelli P; Giacomini A; Rusnati M; Ronca R
Pharmacol Ther; 2017 Nov; 179():171-187. PubMed ID: 28564583
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors.
Doi T; Shitara K; Kojima T; Kuboki Y; Matsubara N; Bando H; Yoh K; Naito Y; Hirai H; Kurokawa Y; Kato T; Morizane C
Cancer Sci; 2023 Feb; 114(2):574-585. PubMed ID: 35838190
[TBL] [Abstract][Full Text] [Related]
16. Identification of residues important both for primary receptor binding and specificity in fibroblast growth factor-7.
Sher I; Lang T; Lubinsky-Mink S; Kuhn J; Adir N; Chatterjee S; Schomburg D; Ron D
J Biol Chem; 2000 Nov; 275(45):34881-6. PubMed ID: 10950949
[TBL] [Abstract][Full Text] [Related]
17. The role of fibroblast growth factors and their receptors in prostate cancer.
Kwabi-Addo B; Ozen M; Ittmann M
Endocr Relat Cancer; 2004 Dec; 11(4):709-24. PubMed ID: 15613447
[TBL] [Abstract][Full Text] [Related]
18. A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors.
Diaz LA; Coughlin CM; Weil SC; Fishel J; Gounder MM; Lawrence S; Azad N; O'Shannessy DJ; Grasso L; Wustner J; Ebel W; Carvajal RD
Clin Cancer Res; 2015 Mar; 21(6):1281-8. PubMed ID: 25398449
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies.
Yamamoto N; Ryoo BY; Keam B; Kudo M; Lin CC; Kunieda F; Ball HA; Moran D; Komatsu K; Takeda K; Fukuda M; Furuse J; Morita S; Doi T
Invest New Drugs; 2020 Apr; 38(2):445-456. PubMed ID: 31041575
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors.
Castelli R; Giacomini A; Anselmi M; Bozza N; Vacondio F; Rivara S; Matarazzo S; Presta M; Mor M; Ronca R
J Med Chem; 2016 May; 59(10):4651-63. PubMed ID: 27138345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
